SCHEDULE: Intracoastal Capital Discloses 4.99% Stake in Enveric

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% beneficial ownership stake in Enveric Biosciences, Inc. common stock.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G disclosing their beneficial ownership in Enveric Biosciences, Inc.
• As of February 2, 2026, the Reporting Persons beneficially own an aggregate of 71,246 shares of Enveric Biosciences, Inc. Common Stock.
• This ownership represents approximately 4.99% of the company's outstanding Common Stock.
• The shares consist of 33,800 shares held directly by Intracoastal and 37,446 shares issuable upon exercise of Intracoastal Warrant 1.
• The beneficial ownership percentage is calculated based on 1,061,533 shares outstanding as of January 27, 2026, plus 328,802 shares issued at the closing of a Securities Purchase Agreement (SPA) and 37,446 shares from Intracoastal Warrant 1.
• The filing indicates shared voting power over 71,246 shares and shared dispositive power over 66,180 shares.
• The Reporting Persons certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive disclosure. The entry of an institutional investor like Intracoastal Capital LLC, even with a passive stake, can be seen as a vote of confidence in Enveric Biosciences, though the 4.99% limit suggests a non-activist position.

Positives

• A significant institutional investor, Intracoastal Capital LLC, has taken a notable stake in Enveric Biosciences, potentially signaling confidence in the company's future prospects.
• The acquisition of shares through a Securities Purchase Agreement suggests a recent capital infusion into Enveric Biosciences.

Negatives

• The presence of blocker provisions in multiple warrants (Intracoastal Warrants 1-5) limits the Reporting Persons' ability to immediately increase their beneficial ownership beyond 4.99%, which could restrict their potential influence or further investment without additional disclosures.

Risks

• The blocker provisions in the warrants prevent the holder from exercising them to the extent that such exercise would result in beneficial ownership of more than 4.99% of the Common Stock, potentially limiting the Reporting Persons' ability to increase their stake or influence without further transactions or waivers.
• The beneficial ownership calculation is based on a specific number of outstanding shares as of January 27, 2026, and subsequent changes in the total number of outstanding shares could alter the reported percentage.

Future Outlook

This filing does not contain forward-looking statements or guidance from Enveric Biosciences, Inc. It primarily details the beneficial ownership of certain reporting persons.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a passive investment by an institutional or significant individual investor. For a biotechnology company like Enveric Biosciences, attracting such investors can be a positive signal, suggesting external validation of its potential, even if the stake is below the 5% threshold that would trigger more active reporting requirements.

Stakeholder Impact

• Shareholders: The disclosure of a new institutional investor could be viewed positively, potentially increasing market confidence. The capital raise associated with this investment provides funding for the company.
• Company Management: The investment provides capital and potentially a supportive, albeit passive, institutional shareholder.

Key Dates

Recommendation

The filing indicates a new passive institutional investor, Intracoastal Capital LLC, has taken a 4.99% stake in Enveric Biosciences. While this is a positive signal of investor confidence and provides capital to the company, a Schedule 13G filing itself does not provide sufficient financial or operational details to warrant a 'buy' or 'sell' recommendation. It suggests a 'hold' as it's a neutral to slightly positive development that doesn't fundamentally alter the investment thesis without further information on the company's performance or strategic direction.

Keywords

Enveric Biosciences, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Biotechnology